Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2...
Assembly Biosciences, Inc. (ASMB)
Last assembly biosciences, inc. earnings: 3/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.assemblybio.com/investor-relations
Company Research
Source: GlobeNewswire
ABI-H0731 + nucleos(t)ide analogs (Nrtl) in patients with chronic Hepatitis B demonstrated favorable longer-term tolerability, greater reductions in HBV DNA and HBV pregenomic (pg) RNA in Phase 2 studies than Nrtl aloneSignificant declines in HBV pgRNA, a surrogate marker of cccDNA, were associated with reductions in hepatitis B viral antigens Company to host conference call today at 8:30am ET SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced that data for its first and second generation HBV core inhibitors were highlighted during today’s late-breaker poster session at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in Boston, Massachusetts. The posters featured final 24-week results and interim long-term data fro
Show less
Read more
Impact Snapshot
Event Time:
ASMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASMB alerts
High impacting Assembly Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ASMB
News
- Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates [Yahoo! Finance]Yahoo! Finance
- Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent UpdatesGlobeNewswire
- Assembly Biosciences, Inc. (NASDAQ: ASMB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366GlobeNewswire
- Assembly Biosciences, Inc. (NASDAQ: ASMB) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $2.00.MarketBeat
ASMB
Earnings
- 5/8/24 - Beat
ASMB
Sec Filings
- 11/19/24 - Form 4
- 11/14/24 - Form SC
- 11/7/24 - Form 8-K
- ASMB's page on the SEC website